Estradiol Gel (Divigel/Elestrin) vs Veozah (Fezolinetant): Side-Effect Profile Head-to-Head

What Are These Two Drugs and Why Are They Being Compared?

Estradiol gel and fezolinetant (Veozah) sit at opposite ends of the menopause pharmacology spectrum. One replaces the hormone your ovaries are making less of. The other works entirely without touching estrogen receptors. Because women are increasingly asking clinicians whether they can skip hormones or whether hormones are safer than the newer non-hormonal options, a direct look at the side-effect data matters.

Estradiol gel, sold as Divigel (0.1% gel in unit-dose packets) and Elestrin (0.06% gel applied to the upper arm), delivers 17-beta-estradiol through the skin. Fezolinetant (Veozah, 45 mg oral tablet once daily) blocks neurokinin 3 (NK3) receptors in the hypothalamus, quieting the KNDy neuron firing that drives hot flashes when estrogen falls. The FDA approved fezolinetant in May 2023 specifically for moderate-to-severe vasomotor symptoms (VMS) in menopause, making it the first NK3 antagonist in this class to reach US women.

No published randomized controlled trial has compared these two drugs head-to-head. The comparisons below are cross-trial syntheses. Where data comes only from individual trials, that is stated explicitly.

How Each Drug Actually Works on a Female Body

Estradiol Gel: Replacing What the Ovary Stopped Making

Transdermal estradiol bypasses first-pass liver metabolism. You apply it to clean, dry skin (upper thigh for Divigel; upper arm for Elestrin), it absorbs over 24 hours, and serum estradiol rises into the low-normal follicular-phase range. This systemic estrogen then acts on hypothalamic thermoregulatory neurons to reduce hot flash frequency and severity and also relieves genitourinary symptoms, protects bone, and may improve sleep and mood.

Because estradiol gel raises circulating estrogen, it triggers all the downstream tissue effects of estrogen: breast tissue stimulation, endometrial stimulation (requiring a progestogen if you still have a uterus), and changes to coagulation proteins, though the transdermal route attenuates many of the liver-driven coagulation effects seen with oral estrogen.

Fezolinetant: A Hormonal System Workaround

Fezolinetant does not touch estrogen receptors. It blocks the NK3 receptor on KNDy neurons in the arcuate nucleus of the hypothalamus. In menopause, these neurons become hyperactivated when estrogen withdrawal removes their usual negative feedback, and they fire in bursts that trigger thermoregulatory responses you experience as hot flashes. In the SKYLIGHT-1 trial (Lancet 2023), fezolinetant 45 mg reduced the frequency of moderate-to-severe hot flashes by approximately 59% from baseline at week 12, compared with approximately 40% in the placebo group, a statistically significant difference.

Because fezolinetant has no estrogenic activity, it does not protect bones, does not relieve vaginal dryness, and does not require a progestogen. It also does not stimulate breast or uterine tissue.

Side-Effect Profiles: The Full Picture

Estradiol Gel Side Effects

The most commonly reported side effects of transdermal estradiol gel are local and hormonal.

Local skin reactions occur in roughly 3-7% of users and include redness, itching, and mild irritation at the application site. Rotating sites and allowing the gel to dry fully before dressing reduces this.

Breast tenderness is the most frequently reported systemic side effect, affecting up to 10-15% of users in the first one to three months. It typically resolves as your body adjusts to a stable estradiol level. Starting at the lowest effective dose (0.25 g Divigel daily or 1.25 g Elestrin daily) and titrating slowly helps.

Headache and nausea are reported in early weeks, again more common when starting at higher doses.

Breakthrough bleeding or spotting can occur if you are in perimenopause or if progestogen timing is suboptimal. This is not a sign of cancer but warrants evaluation if it persists.

Endometrial risk without progestogen is the most clinically serious estrogen-only risk if you have a uterus. Unopposed estrogen causes endometrial hyperplasia and, with long-term use, increases endometrial cancer risk. Co-administration of a progestogen (oral micronized progesterone, a progestin patch, or a hormonal IUD) fully mitigates this risk.

Venous thromboembolism (VTE): This is where the transdermal route matters enormously. A 2019 meta-analysis found that transdermal estradiol was not associated with increased VTE risk, unlike oral estrogen formulations which carry a two- to threefold elevated risk. If you have a personal or family history of clots, transdermal delivery is the preferred route when estrogen therapy is chosen.

Cardiovascular effects: The Women's Health Initiative enrolled women aged 50-79 with a mean age well past the "window of opportunity." Current Menopause Society 2023 position statement guidance confirms that for healthy women under 60 or within 10 years of menopause onset, the cardiovascular risk-benefit ratio for estrogen therapy is favorable.

Fezolinetant (Veozah) Side Effects

The side-effect profile of fezolinetant is meaningfully different because it has no hormonal activity.

Abdominal pain and gastrointestinal symptoms are the most common adverse events, reported in approximately 7-11% of participants across the SKYLIGHT trials. These are usually mild and tend to resolve within the first few weeks.

Liver enzyme elevations are the most significant safety signal specific to fezolinetant. In the SKYLIGHT-1 trial, a small number of participants showed transient alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal. The FDA prescribing information for Veozah therefore requires liver function testing at baseline before starting the drug, then at 3 months and 6 months. Fezolinetant is contraindicated in women with cirrhosis or severe hepatic impairment. If you have a history of autoimmune hepatitis, fatty liver disease, or heavy alcohol use, this is a clinically important consideration your clinician will weigh.

Diarrhea and nausea were reported in 7-9% of study participants, which is comparable to many other once-daily oral medications.

Insomnia was reported slightly more often in fezolinetant users than placebo in some trial arms, though the overall rate was low. This warrants attention because hot flash-related sleep disruption is one of the main reasons women seek treatment in the first place.

No breast or uterine effects: Because fezolinetant carries no estrogenic activity, it does not cause breast tenderness, endometrial stimulation, or spotting. Women who cannot take estrogen (hormone-receptor-positive breast cancer history, unexplained vaginal bleeding, active liver disease not reaching the contraindication threshold for fezolinetant) may find the absence of these effects relevant.

No VTE risk elevation: Fezolinetant has no known association with clotting risk. For women with personal or strong family history of DVT or pulmonary embolism, this is a real advantage over oral estrogen though not over transdermal estradiol.

Side-Effect Comparison at a Glance

| Side effect | Estradiol Gel | Fezolinetant (Veozah) | |---|---|---| | Breast tenderness | 10-15%, usually resolves | None reported | | Local skin irritation | 3-7% | None (oral tablet) | | Nausea / GI upset | Mild, early weeks | 7-9%, mild | | Liver enzyme elevation | Not a known signal | Yes; monitoring required | | VTE risk | Transdermal: not elevated | No signal | | Endometrial risk | Yes (if no progestogen) | None | | Headache | Reported early | Less common | | Vaginal dryness relief | Yes | No | | Bone protection | Yes | No | | Uterine co-treatment needed | Yes (if uterus intact) | No |

Life-Stage Differences: Who Is at Which Stage Matters

The side-effect profile you are most likely to experience and the trade-offs that matter to you change significantly depending on where you are in the menopause transition.

Perimenopause (Typically Ages 40-51)

In perimenopause, your ovaries are still producing estrogen intermittently. Adding estradiol gel on top of unpredictable endogenous production can cause breast tenderness and bloating if estrogen overshoots. Clinicians often start at the lowest dose packet (Divigel 0.25 g) and titrate based on symptom response, not serum level alone, because serum estradiol fluctuates widely in perimenopause.

Fezolinetant has not been studied specifically in women with intact ovarian function who are still having irregular cycles. The prescribing label and the SKYLIGHT trials enrolled postmenopausal women (defined as at least 12 months of amenorrhea). Using fezolinetant in perimenopause is therefore off-label, and the side-effect data from the trials does not directly apply to this group.

Early Postmenopause (Within 10 Years of Final Menstrual Period)

This is the population with the strongest evidence for both drugs. Estradiol gel's systemic estrogen benefits (bone density, cardiovascular metabolic effects, vaginal health) are most pronounced when started in this window. Fezolinetant's data, including SKYLIGHT-1, comes largely from this group.

Late Postmenopause (More Than 10 Years After Final Period)

Starting estrogen therapy more than 10 years after menopause or after age 60 is associated with higher cardiovascular and VTE risk per the Menopause Society guidance. For women in this group who develop new or worsening hot flashes (which does happen), fezolinetant becomes a more attractive first-line option because it avoids the timing-dependent cardiovascular considerations entirely.

Women With PCOS in the Perimenopause Transition

PCOS does not disappear at menopause. Women with PCOS often have higher baseline testosterone and ongoing irregular cycles into their mid-forties, and they reach menopause later on average. In this group, estradiol gel can help with vasomotor symptoms while also providing the systemic estrogen environment that counteracts long-term cardiovascular and metabolic risk. The liver enzyme monitoring required for fezolinetant is also worth noting in women with PCOS who have non-alcoholic fatty liver disease (NAFLD), which is more prevalent in that population.

Pregnancy, Lactation, and Contraception: Required Reading

Both drugs are contraindicated in pregnancy. This is not a theoretical concern. Perimenopause is not infertility. Women in their forties continue to ovulate and conceive, and hot flashes can occur before menstrual cycles have fully stopped.

Estradiol gel in pregnancy: Exogenous estrogen at pharmacologic doses during organogenesis is associated with fetal harm. Estradiol gel is FDA Pregnancy Category X. If you are starting estradiol gel and still have any possibility of ovulation (irregular but not absent periods), you and your clinician must discuss reliable contraception. The gel itself provides no contraceptive effect.

Fezolinetant in pregnancy: Fezolinetant is also contraindicated in pregnancy. Animal reproductive toxicity data raised concern, and no adequate human pregnancy data exist. If there is any chance of pregnancy, contraception is required.

Lactation: Neither drug is recommended during breastfeeding. Estradiol suppresses milk production and transfers into breast milk. Fezolinetant's transfer into human milk has not been studied; given the lack of safety data, it should be avoided.

Practical contraception guidance for perimenopausal women on either drug: Low-dose combined oral contraceptives (if not contraindicated), progestogen-only pills, a hormonal IUD (which also provides the progestogen needed to protect the endometrium when using estradiol gel), or a copper IUD are all options. A clinician can confirm menopause status with FSH testing after age 50 to determine when contraception can be safely stopped (typically after two years of amenorrhea under age 50, one year over age 50 per ACOG guidance).

Who This Is Right For (and Not Right For): By Condition and Life Stage

Estradiol Gel Is Likely a Better Fit If:

• You are in early postmenopause (under 60, within 10 years of your last period) with no contraindications to estrogen
• You want relief from both hot flashes AND genitourinary symptoms (vaginal dryness, urinary urgency, discomfort with sex)
• You have or are at risk for osteoporosis and want the bone-protective effect
• You have elevated VTE risk that rules out oral estrogen but not transdermal delivery
• You are in perimenopause and want cycle regulation alongside symptom control

Estradiol Gel Is Not Appropriate If:

• You have a personal history of hormone-receptor-positive breast cancer
• You have unexplained or undiagnosed vaginal bleeding
• You have active thrombophlebitis or a history of estrogen-sensitive thrombotic events
• You are pregnant or trying to conceive without confirmed inability to ovulate

Fezolinetant (Veozah) Is Likely a Better Fit If:

• You have a hormone-receptor-positive breast cancer history or are on aromatase inhibitor therapy (hot flashes from AI therapy is an off-label but studied use)
• You prefer a non-hormonal mechanism
• You are in late postmenopause where estrogen timing considerations make starting hormone therapy less favorable
• You tried estrogen therapy and could not tolerate breast tenderness or breakthrough bleeding

Fezolinetant Is Not Appropriate If:

• You have cirrhosis or severe hepatic impairment
• You take CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) that significantly raise fezolinetant levels; the FDA label flags this as a contraindication
• You have moderately impaired liver function (use with caution; dose adjustment not established)

Efficacy: What the Numbers Say

Side effects matter more when efficacy is similar, and here the two drugs are reasonably close for the primary symptom of hot flash frequency.

Transdermal estradiol in multiple trials reduces moderate-to-severe hot flash frequency by 70-90% from baseline, typically within 4-8 weeks at adequate doses. In the SKYLIGHT-1 trial, fezolinetant 45 mg reduced frequency by approximately 59% at week 12. Direct comparison is complicated because placebo response rates and baseline frequencies differ across trials.

The Menopause Society notes in its 2023 hormone therapy position statement that hormonal therapy remains the most effective treatment for vasomotor symptoms, with non-hormonal options offering meaningful but generally somewhat lower efficacy. This does not mean Veozah is insufficient for most women; for many, a 59% reduction in hot flash frequency represents a clinically meaningful change in daily life.

For sleep, mood, bone, and genitourinary outcomes, estradiol gel holds a clear advantage. Fezolinetant addresses hot flashes only.

Monitoring and Practical Management

For estradiol gel: No routine bloodwork is required unless your clinician wants to confirm absorption. Application site should be consistent. If you have a uterus, progestogen co-administration is mandatory and should be discussed at the time of prescription. Mammography and breast exams should continue on normal screening schedules per ACOG breast cancer screening guidelines.

For fezolinetant: Liver function tests (ALT, AST, bilirubin) at baseline, 3 months, and 6 months are required per FDA labeling. If ALT rises above three times the upper limit of normal, fezolinetant should be stopped. No dose titration is required; the approved dose is 45 mg once daily. Taking it at the same time each day improves consistency.

A Note on Evidence Gaps in Women

Women have been historically underrepresented in clinical trials across medicine, and menopause pharmacology is no exception. The SKYLIGHT trials did enroll an exclusively female population, which is a strength. But both sets of trials enrolled predominantly white women, limiting generalizability to Black, Hispanic, Asian, and Indigenous women, groups in whom menopause symptom burden, onset age, and duration may differ. Research from the Study of Women's Health Across the Nation (SWAN) found that Black women report more frequent and more bothersome hot flashes than white women, yet their representation in the SKYLIGHT-1 trial was limited. The side-effect data presented in this article reflects trial populations that may not fully represent you.

Can You Switch Between These Two Drugs?

Switching from estradiol gel to fezolinetant, or the reverse, is clinically feasible with some planning.

From estradiol gel to fezolinetant: You can stop estradiol gel and begin fezolinetant. There is no required washout period from a pharmacokinetic standpoint, though some clinicians taper the estradiol dose over 4-6 weeks to avoid a sharp estrogen drop that can temporarily worsen symptoms. If you have been using a progestogen to protect your endometrium, discuss with your clinician whether to continue it; fezolinetant requires no progestogen, but if you switch mid-cycle some clinicians prefer to complete the progestogen course.

From fezolinetant to estradiol gel: Fezolinetant has a short half-life (approximately 10 hours), so it clears within 2-3 days. Starting estradiol gel immediately after stopping fezolinetant is feasible. The endometrium does not require special preparation unless you had bleeding on fezolinetant (which would require evaluation regardless).

Before any switch, a baseline liver function check is required if you are starting fezolinetant. And if you switch to estradiol gel and still have a uterus, progestogen must be added from day one.